4.8 Article

Up-Conversion Y2O3:Yb3+,Er3+ Hollow Spherical Drug Carrier with Improved Degradability for Cancer Treatment

Journal

ACS APPLIED MATERIALS & INTERFACES
Volume 8, Issue 38, Pages 25078-25086

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsami.6b07215

Keywords

Y2O3:Yb3+,Er3+ hollow spheres; degradability; up-conversion luminescence; drug carrier; cancer therapy

Funding

  1. National Natural Science Foundations of China [31470961, 21271059, 21301046, 51302062]
  2. Key Basic Research Special Foundation of Science Technology Ministry of Hebei Province [14961302D]
  3. Hebei Province Hundred Talents Program [BR2-202]
  4. Hebei Province Three Three Three Talents Program [A201401002]
  5. Second Batch of Top Youth Talent Support Program of Hebei Province
  6. Training Program for Innovative Research Team and Leading Talent in Hebei Province University [LJRC024]
  7. Hebei University [2015JQ04, ZD2015031]
  8. Natural Science Foundation of Hebei Province [B2016201209]
  9. SRF for ROCS (SEM)

Ask authors/readers for more resources

The rare earth hollow spheres with up-conversion luminescence properties have shown potential applications in drug delivery and bioimaging fields. However, there have been few reports for the degradation properties of rare earth oxide drug carriers. Herein, uniform and well-dispersed Y2O3:Yb3+,Er3+ hollow spheres (YOHSs) have been fabricated by a general Pechini sol-gel process with melamine formaldehyde colloidal spheres as template. The novel YOHSs with up-conversion luminescence has good drug loading amount and drug-release efficiency; moreover, it exhibits pH-responsive release patterns. In particular, the YOHSs sample exhibits low cytotoxicity and excellent degradable properties in acid buffer. After the sample was loaded with anticancer drug doxorubicin (DOX), the antitumor result in vitro indicates that YOHS-DOX might be effective in cancer treatment. The animal imaging test also reveals that the YOHSs drug carrier can be used as an outstanding luminescent probe for bioimaging in vivo application prospects. The results suggest that the degradable drug carrier with up-conversion luminescence may enhance the delivery efficiency of drugs and improve the cancer therapy in clinical applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available